Background and Significance of Approval

The European Medicines Agency (EMA) has approved Vyndaqel (tafamidis), Pfizer's transthyretin (TTR) stabilizer, marking a new milestone in the treatment of rare diseases. This approval is for the treatment of stage 1 hereditary transthyretin amyloid polyneuropathy (hATTR-PN), and it is the first drug to target the underlying cause of the disease, making it clinically significant. Previously, patients had no alternative other than liver transplantation, but Vyndaqel provides a non-invasive, oral treatment option, significantly improving their quality of life. Through this, Pfizer has strengthened its rare disease portfolio and established a strong position in the high-demand biomarker market.

Analysis of Phase 3 (Fx-005) Trial Results

The pivotal Phase 3 (Fx-005) trial, which served as the basis for this approval, requires a detailed analysis of the efficacy data. In the intent-to-treat (ITT) population, the Neuropathy Impairment Score – Lower Limb (NIS-LL) response rate was 45.3% in the Vyndaqel group and 29.5% in the placebo group, which did not fully meet the statistical significance criterion (p-value 0.068). However, in the actual treatment group (EE) that strictly adhered to the protocol, the response rate in the Vyndaqel group was 60.0%, compared to 38.1% in the placebo group, demonstrating a statistically significant delay (p-value 0.041). Furthermore, the Norfolk QOL score, a quality of life assessment scale, showed a significant reduction in deterioration compared to the placebo group (p-value 0.045), demonstrating its long-term benefits.

Mechanism of Action and Differentiation from Existing Treatments

Vyndaqel has an innovative mechanism that stabilizes the tetramer structure of transthyretin (TTR) protein. It prevents the abnormal dissociation of the protein, which forms amyloid fibrils and accumulates in peripheral nerves, causing nerve damage. This is a paradigm shift from existing symptomatic treatments that only alleviate pain or symptoms, as it inhibits the pathological progression of the disease itself. In particular, it has become a key drug for early-stage treatment in patients diagnosed early due to genetic mutations, slowing down irreversible nerve degeneration.

Challenges in Market Access, Including Pricing and Reimbursement

After entering the European market, actual sales will depend on overcoming the barriers to price negotiations with national health authorities and reimbursement listing. Vyndaqel, designated as an orphan drug, underwent a rapid review process, but it is facing strong demands for cost-effectiveness validation due to its high price, which is proportional to its innovation. Governments are likely to propose price restrictions or risk-sharing schemes in the process of introducing expensive rare disease treatments within limited budgets. Therefore, it is essential for Pfizer to develop a sophisticated country-specific pricing strategy and accumulate real-world data (RWD) to ensure early patient access and increase prescription rates.

Market Size Forecast and Changes in Competitive Landscape

Vyndaqel has successfully established itself in the market after approval and has grown into a mega-blockbuster drug with annual sales of approximately $6.3 billion by 2025. However, despite its first-mover advantage, the market landscape is changing with the launch of second-generation RNA interference (RNAi)-based targeted therapies such as Alnylam's Onpattro and Amvuttra. In addition, AstraZeneca and Ionis' Wainua, and BridgeBio's Acoramidis, are also entering the market. In this competitive environment, Pfizer plans to defend its market dominance until the expiration of its existing patent in 2031 by expanding the indication to include transthyretin amyloid cardiomyopathy (ATTR-CM) and improving the formulation.